HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
HCW Biologics announced that its TGF-β trap and IL-15 fusion moiety promotes expansion of CD8+ T cells and NK cells, demonstrating clinical benefit in cancer patients and activity against HIV-1 and bronchopulmonary dysplasia. The company has incorporated this discovery into second-generation T Cell Engager (HCW11-018b) and Immune Checkpoint Inhibitor (HCW11-040) programs, with both candidates at IND-enabling stage and clinical studies planned for 2027.